Bank of America’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Bank of America’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-13	Closed	-$113	–	8505
2024 Q2	$113	Buy	+13	New	+$115	﹤0.01%	7676
2023 Q1	–	Sell	-3	Closed	-$18	–	8397
2022 Q4	$18	Sell	3 -8	-73%	-$70	﹤0.01%	8004
2022 Q3	$0	Hold	11	–	–	﹤0.01%	8293
2022 Q2	$0	Sell	11 -2,453	-100%	-$38.8K	﹤0.01%	8515
2022 Q1	$52K	Sell	2,464 -738	-23%	-$25.5K	﹤0.01%	7163
2021 Q4	$193K	Sell	3,202 -1,158	-27%	-$86.6K	﹤0.01%	6515
2021 Q3	$409K	Buy	4,360 +2,974	+215%	+$396K	﹤0.01%	5793
2021 Q2	$230K	Sell	1,386 -1,051	-43%	-$179K	﹤0.01%	5997
2021 Q1	$470K	Buy	+2,437	New	+$608K	﹤0.01%	5424

Other funds holding TLIS

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Bank of America's TLIS Position: Q3 2024 in Review

Bank of America sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 13 shares — an estimated $113 sold.

Bank of America first reported a position in TLIS in Q1 2021 and held it in 9 quarters. The position peaked at $470K in Q1 2021. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

Bank of America reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
Bank of America sold 13 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $113.
Bank of America first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 9 quarters.
Bank of America's Talis Biomedical Corporation Common Stock position peaked at $470K in Q1 2021.
2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on Bank of America's 13F filing for Q3 2024, filed 14 Nov 2024.